301 hasil
Menampilkan 1–20 · 0,14 detik · RSS
Molecular Therapy: Oncology
Scopus
ISSN 2950-3299 · Elsevier · 301 artikel di indeks
-
Artikel Jurnal
Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics
Human adenoviruses (HAdVs) are enjoying a renaissance in interest for the development of cancer therapies following the approval of Adstiladrin (Ferring Pharmaceuticals) for the treatment of bladder cancer, strong phase 3 data from CG Oncology’s cretostimogene grenadenorepvec, and many other…
-
Artikel Jurnal
Beyond autologous ex vivo CAR-expressing cell therapies: Toward allogeneic and nucleated cell-free delivery systems of CAR
The success of ex vivo chimeric antigen receptor (CAR)-T cell therapies has transformed the treatment of hematologic malignancies but remains limited by individualized manufacturing complexity and cost. Emerging in situ and in vivo CAR engineering platforms aim to overcome these barriers by…
-
Artikel Jurnal
Enhancing cancer killing and natural killer cell persistence by targeting NOXA, a predictor of poor patient survival
Natural killer (NK)-cell-based therapeutics have emerged as promising modalities in cancer immunotherapy due to their potent ability to target and kill cancer cells. However, their clinical efficacy is often constrained by the limited in vivo persistence of NK, which hinders sustained therapeutic…
-
Artikel Jurnal
Targeted therapies in pediatric oncology: A start
The treatment of cancers was revolutionized by the use of combination “conventional” chemotherapy, first in children, during the 20th century. That foundation of therapy, while having achieved significant advances in survival, has reached its limits. Innovations in targeted therapies are now…
-
Artikel Jurnal
Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
Low-grade gliomas (LGGs) are the most common brain tumors diagnosed in adolescents and young adults. LGGs demonstrate a longer latency and are associated with a lower relative risk compared to high-grade gliomas (HGGs), despite their potential to malignantly transform into fatal HGGs. We previously…
-
Artikel Jurnal
The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines
NUT carcinoma (NC) is a rare, yet aggressive disease (median survival of 6.5 months) of the young defined by a translocation of the nuclear protein in testis gene 1 (NUTM1). Neither surgery nor radiochemotherapy or targeted therapies provide effective disease control, thereby creating a need for…
-
Artikel Jurnal
A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct
CD70, a member of the tumor necrosis factor receptor superfamily, is expressed in glioblastoma (GB), where it promotes tumor growth, migration, and immunosuppression. Accordingly, it has emerged as a target for chimeric antigen receptor (CAR)-T cell therapy. Despite the influence of CAR structure…
-
Artikel Jurnal
Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias
Hematopoietic stem cell transplantation (HSCT) can promote durable long-term remissions for children and adolescents with high-risk acute leukemias. While many patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) can achieve a cure, post-HSCT relapse remains a…
-
Artikel Jurnal
Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression. This molecular profile limits responsiveness to hormonal or targeted therapies, often with poor outcomes and high…
-
Artikel Jurnal
Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD
The oncolytic adenovirus Ad5-delta-24-RGD (Ad5Δ24RGD) exhibits suboptimal therapeutic efficacy in high-grade glioma. Here, we show that combining two specific potency-enhancing mutations in E3-19K and i-leader (designated 19KSS-iLQ125Ter) markedly increases the cytolytic efficiency and the size of…
-
Artikel Jurnal
Engineering “off-the-shelf” TCR-T cells: A transient mRNA platform for balanced alloreactivity and functionality
Adoptive T cell therapy using T cell receptor (TCR)-engineered T (TCR-T) cells shows promise for the treatment of cancer. Our lab employs mRNA electroporation to redirect T cell specificity toward HBV antigens expressed on HBV-related HCC, while exploiting mRNA’s transient nature to limit toxicity…
-
Artikel Jurnal
FOXM1 drives cisplatin resistance in ovarian cancer through STIM1-mediated SOCE and STAT1 activation
Cisplatin resistance remains a major challenge in ovarian cancer, limiting treatment efficacy and reducing patient survival. While FOXM1 and calcium (Ca 2+ signaling have been individually implicated in chemoresistance, how transcriptional regulation is linked to Ca 2+ -dependent survival signaling…
-
Artikel Jurnal
Preclinical evaluation of triple-mutated oncolytic herpes virus expressing fusion-type interleukin 12 for malignant melanoma
G47Δ, a triple-mutated oncolytic herpes simplex virus type 1 (HSV-1) marketing-approved for malignant glioma, has demonstrated high efficacy including survival benefits via robust oncolytic activities with efficient antitumor immunity induction. G47Δ-based, oncolytic HSV-1 expressing fusion-type…